JP Morgan Chase’s Regencell Bioscience RGC Stock Holding History

JP Morgan Chase’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-5,000	Closed	-$117K	–	8019
2026 Q1	$117K	Buy	+5,000	New	+$141K	﹤0.01%	5751

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Amundi Paris, France $416B AUM 44.19% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

JP Morgan Chase's RGC Position: Q2 2026 in Review

JP Morgan Chase sold out of Regencell Bioscience (RGC) in Q2 2026, closing a stake of 845 shares — an estimated $19.7K sold.

JP Morgan Chase first reported a position in RGC in Q1 2026 and held it in 1 quarter. The position peaked at $19.7K in Q1 2026. 35 funds tracked by Wall St. Rank hold RGC as of Q2 2026.

JP Morgan Chase reported no remaining Regencell Bioscience position as of Q2 2026 after selling out during the quarter.
JP Morgan Chase sold 845 Regencell Bioscience shares in Q2 2026, an estimated $19.7K.
JP Morgan Chase first reported a position in Regencell Bioscience in Q1 2026 and held it in 1 quarter.
JP Morgan Chase's Regencell Bioscience position peaked at $19.7K in Q1 2026.
35 funds tracked by Wall St. Rank held Regencell Bioscience as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.